FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and concerns a pharmaceutical composition for inducing an immune response on tumour-associated macrophagues containing a mini-gene DNA construct which codes a polypeptide in a pharmaceutically acceptable carrier wherein the polypeptide contains three immunogenic legumain fragments bonded together with linker peptides, and wherein each linker peptide consists of the AAA or AAY sequence.
EFFECT: invention provides effective control of breast carcinoma, non-small-cell lung cancer and colorectal carcinoma.
8 cl, 2 ex, 26 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DNA-VACCINE AGAINST TUMORAL GROWTH AND WAYS OF THEIR APPLICATION | 2004 |
|
RU2343195C2 |
| IMMUNOPROPHYLACTIC CANCER VACCINE | 2004 |
|
RU2556128C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC FOR LEGUMAIN | 2013 |
|
RU2574203C2 |
| PREVENTIVE CANCER VACCINE | 2004 |
|
RU2385163C2 |
| IDENTIFICATION OF TUMOUR-ASSOCIATED ANTIGENS FOR DIAGNOSTICS AND THERAPY | 2013 |
|
RU2644686C2 |
| FUSED PROTEINS WITH IMMUNOGLOBULIN FC-FRAGMENT FOR ENHANCING IMMUNOGENICITY OF PROTEIN AND PEPTIDE ANTIGENS | 2000 |
|
RU2248214C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| MODIFIED EPITOPES FOR AMPLIFYING RESPONSES OF CD4+ T-CELLS | 2013 |
|
RU2724994C2 |
| ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND APPLICATION THEREOF | 2015 |
|
RU2661678C1 |
| CONJUGATES FOR ADMINISTERING BIOLOGICALLY ACTIVE COMPOUNDS | 2009 |
|
RU2567667C2 |
